STADA Arzneimittel AG / Corporate Action/Issue of Debt 14.04.2010 16:19 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- STADA Arzneimittel AG today on April 14, 2010, successfully placed a bond with a volume of EUR 350 million. STADA intends to use the proceeds from the emission for general business purposes. The bond has a term of five years with an annual interest rate of 4.00%. The issue price amounts to 99.987%. The denomination is EUR 1,000. It is planned to authorize the bond for the Luxembourg Securities Market. The identification numbers are: WKN: A1DAGK, ISIN: XS0503278847, Common Code: 050327884. The bond was placed both at institutional investors and private investors in more than 15 countries. The order book for the emission was more than seven times oversubscribed. The joint lead managers for this transaction are Commerzbank Aktiengesellschaft, Deutsche Bank AG, DZ BANK AG and The Royal Bank of Scotland plc. Deutsche Apotheker- und Ãrztebank eG, HSBC Trinkaus & Burkhardt AG, WestLB AG and Bankhaus Lampe KG act as co-lead managers. Additional information: STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 / 61118 Bad Vilbel, Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail: communications@stada.de Or visit us in the Internet at www.stada.com. ************************* For information regarding the securities mentioned in this corporate news, please refer to the respective securities prospectus dated 13 April 2010, published on the website of Luxemburg Stock Exchange (www.boerse.lu). Nothing in this corporate news constitutes an offer of securities, an invitation to subscribe for securities, any advice or other service in relation to the securities, nor does it qualify as a contractual or other obligation in relation to the securities. In particular, the securities referred to in this corporate news have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended. The securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the Securities Act). Information contained in this corporate news may not be forwarded or distributed to any person or address in the United States. 14.04.2010 16:19 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|] --------------------------------------------------------------------------- Language: English Company: STADA Arzneimittel AG StadastraÃe 2-18 61118 Bad Vilbel Deutschland Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: communications@stada.de Internet: www.stada.de ISIN: DE0007251803, DE0007251845, WKN: 725180, 725184, Indices: MDAX Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf; Freiverkehr in Berlin, Hannover, München, Hamburg, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-News: STADA: STADA Arzneimittel AG successfully places EUR 350 million bond
| Source: EQS Group AG